Which chemotherapy agents are commonly associated with CIPN?

Which chemotherapy agents are commonly associated with CIPN?

• A. Anthracyclines and Alkylating Agents
• B. Platinum Agents, Taxanes, and Vinca Alkaloids
• C. Antimetabolites and Hormonal Therapies
• D. Topoisomerase Inhibitors and Antimicrotubular Agents

Answer: (B)

CIPN arises when certain chemotherapies damage peripheral nerves, and three classes are most commonly linked to this toxicity: platinum agents, taxanes, and vinca alkaloids. Platinum compounds (like cisplatin, carboplatin, and oxaliplatin) damage dorsal root ganglion neurons, leading to predominantly sensory symptoms such as numbness, tingling, and loss of vibration or proprioception; oxaliplatin can also cause acute cold-induced dysesthesias. Taxanes (paclitaxel, docetaxel, cabazitaxel) disrupt microtubule function and axonal transport, producing dose-dependent sensory neuropathy that can be persistent. Vinca alkaloids (vincristine, vinblastine, vinorelbine) inhibit microtubule assembly, causing neuropathy that often includes sensory and sometimes motor components. These effects are more characteristic and commonly observed with these agents than with other drug classes, which is why this combination best explains CIPN risk.

CIPN arises when certain chemotherapies damage peripheral nerves, and three classes are most commonly linked to this toxicity: platinum agents, taxanes, and vinca alkaloids. Platinum compounds (like cisplatin, carboplatin, and oxaliplatin) damage dorsal root ganglion neurons, leading to predominantly sensory symptoms such as numbness, tingling, and loss of vibration or proprioception; oxaliplatin can also cause acute cold-induced dysesthesias. Taxanes (paclitaxel, docetaxel, cabazitaxel) disrupt microtubule function and axonal transport, producing dose-dependent sensory neuropathy that can be persistent. Vinca alkaloids (vincristine, vinblastine, vinorelbine) inhibit microtubule assembly, causing neuropathy that often includes sensory and sometimes motor components. These effects are more characteristic and commonly observed with these agents than with other drug classes, which is why this combination best explains CIPN risk.